Genomic Vision Completed the First Step in genetic characterization

Genomic Vision, a biotechnology company that develops tools and services dedicated to the analysis and control of changes in the genome, today announces that they have completed work package one of a three-part research agreement for the genetic characterization of Sanofi cell banks.In 2019 Genomic Vision started the first part of a partnership with Sanofi Genzyme which is the speciality care global business unit of Sanofi, to characterize transformed cell lines for bio-production and to compare proprietary molecular combing technology with other laboratory methods

The results obtained in this first milestone consolidated the working hypothesis and created a way to a better understanding of the genetic characterization of transformed cell lines. Molecular combing with the FiberVision® product lines provides a single-molecule visual output of transgene integration patterns with high sensitivity and quantitative results, without amplification bias.

France based biotechnology company used this method to monitor the quality of cell lines and assess their stability throughout the manufacturing process, an essential step in the development and production of numerous biological products including viral particles, recombinant therapeutic proteins, monoclonal antibodies as well as contributing to vaccine production.

Dominique Remy-Renou, CEO of Genomic Vision said that with the resolution, visualization, and sensitivity being key requirements for genetic stability and clonality testing, molecular combing is poised to help create a new benchmark for bioproduction and cell line manufacturing. She also added that the company continues to work with the National Institute of Standards and Technology consortium to develop quality control tools to be used in genome editing-based therapies. These tools are used for monitoring DNA replication in the cancerous cell, for early cancer detection and the diagnosis of genetic diseases.